Microbiome and Cancers, With Focus on Genitourinary Tumors

1 Section of Pathological Anatomy, School of Medicine, United Hospitals, Polytechnic University of the Marche Region, Ancona, Italy, Oncology Unit, Macerata Hospital, Macerata, Italy, Division of Oncology, S. Orsola-Malpighi Hospital, Bologna, Italy, Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, United States, Department of Pathology and Surgery, Faculty of Medicine, Cordoba, Spain

[1]  S. Boorjian,et al.  The Microbiome and Genitourinary Cancer: A Collaborative Review. , 2019, European urology.

[2]  A. Salonia,et al.  Analysis of the Enteric Microbiome: First Tentative Steps Towards a Comprehensive Work-up of Prostate Cancer? , 2018, European urology.

[3]  D. Ankerst,et al.  Metabolic Biosynthesis Pathways Identified from Fecal Microbiome Associated with Prostate Cancer. , 2018, European urology.

[4]  K. Pienta,et al.  Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies , 2018, Prostate Cancer and Prostatic Diseases.

[5]  R. Montironi,et al.  Re: Gut Microbiome Influences Efficacy of PD-1-based Immunotherapy Against Epithelial Tumors. , 2018, European urology.

[6]  L. Zitvogel,et al.  Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  Peng Wu,et al.  Profiling the Urinary Microbiota in Male Patients With Bladder Cancer in China , 2018, Front. Cell. Infect. Microbiol..

[8]  Brian Goodman,et al.  The microbiome and cancer , 2018, The Journal of pathology.

[9]  G. Reid.  Microbes in food to treat and prevent disease , 2018 .

[10]  Laurence Zitvogel,et al.  Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors , 2018, Science.

[11]  Donna Neuberg,et al.  Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer , 2017, Science.

[12]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[13]  H. Moch,et al.  Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future Perspectives. , 2017, Current drug metabolism.

[14]  F. Montorsi,et al.  The Microbiome of the Prostate Tumor Microenvironment. , 2017, European Urology.

[15]  Arthur Brady,et al.  Strains, functions and dynamics in the expanded Human Microbiome Project , 2017, Nature.

[16]  Noam Shental,et al.  Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine , 2017, Science.

[17]  M. Socinski,et al.  First‐Line Nivolumab in Stage IV or Recurrent Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[18]  K. Schalper,et al.  Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis. , 2017, JCO precision oncology.

[19]  Nadeem Riaz,et al.  Recurrent SERPINB3 and SERPINB4 Mutations in Patients that Respond to Anti-CTLA4 Immunotherapy , 2016, Nature Genetics.

[20]  S. Love,et al.  Characterization of the microbiome of nipple aspirate fluid of breast cancer survivors , 2016, Scientific Reports.

[21]  Erik J. Snider,et al.  Potential Role of the Microbiome in Barrett’s Esophagus and Esophageal Adenocarcinoma , 2016, Digestive Diseases and Sciences.

[22]  A. Ribas,et al.  Combination cancer immunotherapies tailored to the tumour microenvironment , 2016, Nature Reviews Clinical Oncology.

[23]  Shohei Koyama,et al.  Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints , 2016, Nature Communications.

[24]  Xin Wang,et al.  Effectiveness of anti-PD-1/PD-L1 antibodies in urothelial carcinoma patients with different PD-L1 expression levels: a meta-analysis , 2015, Oncotarget.

[25]  T. Gajewski,et al.  Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity , 2015, Nature.

[26]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[27]  T. Schumacher,et al.  Neoantigens in cancer immunotherapy , 2015, Science.

[28]  S. Kang,et al.  Short chain fatty acids induce both effector and regulatory T cells by suppression of histone deacetylases and regulation of the mTOR-S6K pathway , 2014, Mucosal Immunology.

[29]  J. Shamonki,et al.  Microbial Dysbiosis Is Associated with Human Breast Cancer , 2014, PloS one.

[30]  W. Garrett,et al.  The Microbial Metabolites, Short-Chain Fatty Acids, Regulate Colonic Treg Cell Homeostasis , 2013, Science.

[31]  Liang Zhou,et al.  The Composition of Microbiome in Larynx and the Throat Biodiversity between Laryngeal Squamous Cell Carcinoma Patients and Control Population , 2013, PloS one.

[32]  B. Birren,et al.  Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. , 2012, Genome research.

[33]  P. Bork,et al.  Enterotypes of the human gut microbiome , 2011, Nature.

[34]  D. Nie,et al.  G‐protein‐coupled receptor for short‐chain fatty acids suppresses colon cancer , 2011, International journal of cancer.

[35]  Zhiheng Pei,et al.  Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome. , 2009, Gastroenterology.

[36]  W. Isaacs,et al.  A molecular analysis of prokaryotic and viral DNA sequences in prostate tissue from patients with prostate cancer indicates the presence of multiple and diverse microorganisms , 2008, The Prostate.

[37]  F. Schmidt.  Meta-Analysis , 2008 .

[38]  W. Faulk,et al.  Short-chain fatty acids modulate gene expression for vascular endothelial cell adhesion molecules. , 2005, Nutrition.

[39]  A. Partin,et al.  Profiling the Urinary Microbiome in Men with Positive versus Negative Biopsies for Prostate Cancer , 2018, The Journal of urology.

[40]  C. Huttenhower,et al.  The Role of Gut Microbiome in the Pathogenesis of Prostate Cancer: A Prospective, Pilot Study. , 2018, Urology.

[41]  K. Schalper,et al.  Programmed Cell Death 1 ( PD-1 ) Ligand ( PD-L 1 ) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1 / PD-L 1 Axis Inhibitors : A Systematic Review and Meta-Analysis , 2017 .

[42]  H. Mollenkopf,et al.  Prevalence of Propionibacterium acnes in diseased prostates and its inflammatory and transforming activity on prostate epithelial cells. , 2011, International journal of medical microbiology : IJMM.